GROWTH OPPORTUNITIES IN RESPIRATORY AND NEUROLOGICAL DISEASE MANAGEMENT, RNA THERAPEUTICS, AND DRUGS FOR OBESITY AND RARE DISEASES

GROWTH OPPORTUNITIES IN RESPIRATORY AND NEUROLOGICAL DISEASE MANAGEMENT, RNA THERAPEUTICS, AND DRUGS FOR OBESITY AND RARE DISEASES

 

RELEASE DATE
16-Jul-2021
REGION
Global
Research Code: D759-00-22-00-00
SKU: HC03432-GL-TA_25589
$950.00
In stock
SKU
HC03432-GL-TA_25589
$950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) covers innovations in therapeutics development and improvement of adherence for asthma and other obstructive respiratory diseases. It also covers emerging therapeutic modalities for neurological diseases, including orally delivered small molecules, disease modifying therapies for Alzheimer’s and other neurodegenerative diseases. Further, innovations in RNA therapeutics and developments in delivery of RNAi have been discussed. A few innovations covering obesity management and personalized obesity diagnosis based on phenotype are also covered.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Asthma, RNA therapeutics, clinical decision support, AI enabled asthma diagnosis, gene therapy, RNA modulation, small molecules, respiratory disease, obesity, obesity phenotype, cell-free biomanufacturing, DNA flow reactor, antisense therapy, antisense oligonucleotides, RNA interference, RNAi, self-delivering RNAi, neuroprotection, neurodegeneration, oral small molecule, neuroimmunology

Table of Contents

INNOVATIONS IN LIFE SCIENCES, HEALTH & WELLNESS

  • KNOPP BIOSCIENCES, US
  • CLIN-E-CAL LTD, UK
  • VIDA DIAGNOSTICS, US
  • ARCELLX, US
  • LOCANABIO, US
  • LOBESITY, US
  • PHENOMIX SCIENCES, US
  • STABLIX, US
  • ALLOGENEIC CELLULAR THERAPY FOR BONE DISORDERS
  • OFF-THE-SHELF PRODUCT FOR BONE DISORDERS
  • ALECTOR INC.—INVESTOR DASHBOARD
  • ORAL SMALL-MOLECULE THERAPEUTIC FOR ALZHEIMER’S DISEASE
  • TARGETED INHIBITION OF AMYLOID OLIGOMERS
  • ALZHEON—INVESTOR DASHBOARD
  • RNA-TARGETED THERAPY FOR NEURODEGENERATIVE DISEASES
  • ANTISENSE THERAPY FOR TREATING UNDRUGGABLE DISEASES
  • IONIS PHARMACEUTICALS—INVESTOR DASHBOARD
  • TYROSINE KINASE INHIBITION FOR MULTIPLE DISEASE AREAS
  • TYROSINE KINASE INHIBITION TARGETING MAST AND GLIAL CELLS
  • AB SCIENCE S.A.—INVESTOR DASHBOARD
  • SMALL MOLECULE THERAPY FOR NEURODEGENERATION
  • ORAL ANTI-INFLAMMATORY THERAPY FOR NEUROPROTECTION
  • MEDICINOVA INC., US–INVESTOR DASHBOARD
  • PHIO PHARMACEUTICALS, US
  • FABRICNANO, UK

KEY CONTACTS

  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • LEGAL DISCLAIMER
Related Research
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) covers innovations in therapeutics development and improvement of adherence for asthma and other obstructive respiratory diseases. It also covers emerging therapeutic modalities for neurological diseases, including orally delivered small molecules, disease modifying therapies for Alzheimer’s and other neurodegenerative diseases. Further, innovations in RNA therapeutics and developments in delivery of RNAi have been discussed. A few innovations covering obesity management and personalized obesity diagnosis based on phenotype are also covered. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Asthma, RNA therapeutics, clinical decision support, AI enabled asthma diagnosis, gene therapy, RNA modulation, small molecules, respiratory disease, obesity, obesity phenotype, cell-free biomanufacturing, DNA flow reactor, antisense therapy, antisense oligonucleotides, RNA interference, RNAi, self-delivering RNAi, neuroprotection, neurodegeneration, oral small molecule, neuroimmunology
More Information
No Index No
Podcast No
Industries Healthcare
WIP Number D759-00-22-00-00
Is Prebook No
Ti Codes D759